Engagement The Board of Directors has a strong focus on engaging with a broad range of stakeholders both within CSL and externally. To support engagement with these diverse parties the Board always takes time to visit different locations throughout CSL’s global network. In September 2024 the Board visited CSL’s European operations, including manufacturing plants and research and development facilities in Liverpool (UK), Bern (Switzerland) and Marburg (Germany). In June 2025 the Board held its meeting in Amsterdam, Netherlands, where it met with key external stakeholders including health economists, supply chain partners and researchers. We also celebrated the 25th anniversary of our manufacturing facility in Bern. This event underlined how integral CSL’s acquisition of ZLB in 2000 was to our growth and how important the company’s ongoing contribution is to the Swiss economy. I and some of my colleagues spend time each year meeting with our shareholders. These meetings allow us to listen to feedback from our investors, which we value greatly. One topic we know is top of mind for our shareholders is remuneration. Our investors sent a message at the Annual General Meeting in October – and we continue to listen. You can find the details on remuneration on page 61 of this report. We will continue to listen and respond to feedback in relation to our remuneration approach as well as any other issues important to our shareholders. Your Board is confident in the outlook for CSL and for our ability to deliver enduring patient impact in areas of high unmet medical need. Achieving this will allow us to provide sustainable, profitable growth for our shareholders. Once again, on behalf of the Board, I’d like to extend my thanks for your support. “The detail in this report shows our strategic ambition of delivering enduring patient impact in areas of high unmet medical need. This underpins value creation for shareholders into the future. It’s what we’ve always done.” Dr Brian McNamee AO Chairman 5 CSL Limited Annual Report 2024/25
RkJQdWJsaXNoZXIy MjE2NDg3